Applications of Ticlopidine in Industrial Manufacturing

As a direct manufacturer of pharmaceutical-grade Ticlopidine, we support established downstream industries that rely on this material for advanced synthesis and specialized finished goods. Our production aligns with stringent global standards, ensuring traceable quality and consistent technical support for each application scenario.

1. Antiplatelet Pharmaceutical Production

Leading pharmaceutical manufacturers utilize Ticlopidine as the core API for oral antiplatelet formulations, primarily indicated for the reduction of stroke risk and to prevent thrombotic events. Companies integrate pharmaceutical-grade Ticlopidine into their GMP-compliant tableting or encapsulation lines, balancing pharmacopoeia-guided dosage and multi-step QC requirements. Process engineers optimize inclusion rates to meet both local regulatory dosage ceilings and release profile targets in single-ingredient and fixed-dose combination drugs.

Industry compliance standards

• United States Pharmacopeia (USP)
• European Pharmacopoeia (Ph. Eur.)
• Current Good Manufacturing Practice (cGMP) per 21 CFR Parts 210 & 211
• World Health Organization (WHO) prequalification norms for antiplatelet APIs

Typical usage ratio

• 150–300 mg API per tablet or capsule, adjusted based on local product registration dossiers and target indication
• Formulation loadings typically represent 10–25% of the solid dose’s net weight

Downstream process integration

• Direct weighing and blending with excipients at the dry mixing stage; option for wet granulation for controlled release forms
• Validation sampling and in-process content assays before compression or encapsulation

Final product types

• Prescription antiplatelet tablets (immediate release and extended release)
• Ticlopidine-containing hard or soft gelatin capsules

2. Laboratory Reference Standards Manufacturing

Accredited producers of certified laboratory reference standards employ Ticlopidine as a traceable source material for calibration and analytical controls. These standards are essential for pharmaceutical QC labs, clinical environments, and forensic applications requiring validated chromatographic and spectrophotometric methods. Proper traceability and purity characterization are mandatory, with batch-level documentation supporting international laboratory accreditation schemes.

Industry compliance standards

• ISO 17034 Reference Material Producer accreditation
• ISO/IEC 17025 laboratory requirements for testing and calibration
• FDA and EMA guidance on analytical reference material qualification
• Pharmacopoeial monograph methods (USP, EP) for assay, purity, and identity

Typical usage ratio

• Reference standard purity levels must exceed 98.5%, with unit sizes from 1 mg to 100 mg depending on client validation scope
• Standard solution concentrations typically range from 0.1 mg/mL to 10 mg/mL

Downstream process integration

• Bulk compound dissolved, aliquoted, and stabilized in pre-weighed vials under inert gas where required for long-term storage
• Homogeneity and stability assays performed on each reference batch prior to release

Final product types

• Ticlopidine reference standards for HPLC, GC-MS, and LC-MS validation
• Certified reference solutions for proficiency testing and quality control labs

3. Bulk Drug Substance (BDS) Intermediate Supply

European and North American bulk pharmaceutical ingredient (BPI) manufacturers source high-purity Ticlopidine for BDS stages, particularly where the active intermediate forms part of a vertically integrated or contract API supply chain. These processes apply multi-stage purification and customized micronization, guided by regulatory filings and technical transfer agreements. Trace impurity control and particle size specification are crucial for downstream API conversion.

Industry compliance standards

• ICH Q7 guidelines for API manufacturing
• EDQM CEP certification for substances exported to Europe
• Japanese Pharmacopoeia (JP) for exports to Japan
• Drug Master File (DMF) requirements per FDA

Typical usage ratio

• Input as 100% neat compound at process scale from 1 kg to 250 kg per campaign
• Yield and loss tolerance determined by downstream conversion and purification requirements (yields typically 85–98%)

Downstream process integration

• Integration at semi-synthetic stage, commonly involving crystallization, micronization, and solvent exchange under cGMP batch records
• Automated transfer to API finishing facilities

Final product types

• GMP-certified API for global export
• Intermediates for contract pharmaceutical manufacturing organizations (CMOs)

4. Clinical Trials Supply Manufacturing

Leading clinical contract manufacturers depend on Ticlopidine as an investigational API input for phase I–III trials, and for developing generic pipeline candidates in new dosage formats. Strict chain-of-custody and batch traceability apply at every step, and manufacturers conduct stability trial packaging for site-specific distribution. The supply supports customized batch sizes with finely controlled quality release criteria and expedited production cycles.

Industry compliance standards

• ICH Q1A(R2) stability testing guidelines
• GMP for Investigational Medicinal Products (IMP) as per EU Annex 13 and FDA 21 CFR Part 312
• Clinical trial supply chain auditing by GCP requirements
• WHO guidelines for IMP randomization and blinding

Typical usage ratio

• API concentration typically mirrors commercial dosages (150–250 mg per solid oral dosage form)
• Custom forms may test micro-dosed strengths (10–100 mg) for PK or safety studies

Downstream process integration

• Entry at encapsulation or tablet compression, using split batch records and double-blind QC checks
• Randomized packaging into low-count blisters, bottles, or sachets per trial design

Final product types

• IMP-labeled tablets or capsules for clinical research centers
• Comparator and placebo products in various dosage forms for bioequivalence and crossover studies